

IBC

INNOVATION BIOMEDICAL CENTER



View of the Innovation Biomedical Center.

The management of the IEM decided to establish the Innovation Biomedical Center (IBC) on the basis of medical market demand and in an effort to enhance the innovative potential of the IEM's scientific outputs and the effectiveness of their transfer to medical practice. The innovation process is essentially wedded to entrepreneurship; therefore the IBC's activities are oriented towards the support and development of small spin-off firms.

The Innovation Biomedical Center is a newly built facility located in the close vicinity of the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, in Prague-Krč. It was constructed from August 2007 to March 2008. The project was financed with contributions from the EU and the city of Prague.

The Science and Technology Parks Association of the CR awarded the Innovation Biomedicine Center accreditation in October 2008.

The goal of the IBC project is to build the complex infrastructure necessary for technology transfer from the IEM through applied research and innovative entrepreneurship to the medical market place.

The vision of the IBC is to become the key center in the field of cell-based therapies and their transfer to medical practice in the Czech Republic, and to take part in world networks in this field.

The mission of the IBC is to stimulate research outputs and their commercialization by providing favorable conditions for the emergence and development of spin-off firms with innovative potential in the field of biomedicine.



The IBC promotes the use of IEM technology to benefit the IEM through licensing inventions to spin-off companies capable of successfully commercializing them. It supports the research mission of the IEM by finding industrial partners for spin-off firms, sponsoring research and generating licensing income that supports future research. The IBC earns a fair return and increases the recognition of the IEM and the inventors, thus contributing to the growth of the spin-off firms and the development of the IEM. The IBC helps move technologies from the IEM's laboratories to the marketplace by developing and managing an array of partnerships with the private sector. Successful technology transfer involves a number of steps, beginning with the invention of new technology. These inventions are evaluated, then if appropriate,



intellectual property protection (patents or copyright) is sought. Collaborative research with industry may further develop the technology, which may then be promoted and, hopefully, licensed.

THE INNOVATION BIOMEDICINE CENTER HAS THREE COMPONENTS

Center of Support for Competitiveness in Biomedicine

– provides offices and a small conference room for activities focused on training, consultation and legal support in biomedicine.

Center of Applied Research in Biomedicine

– offers laboratories for applied research and scale-up technologies, focused on regenerative medicine, cell therapy, the development of biomaterials and pharmaceuticals as well as the design of clinical studies.

Business Incubator (office area, GMP-certified clean rooms) for spin-off companies. The companies housed in the incubator benefit from shared consultation, patent, tax and other services and take advantage of opportunities to participate in applied research projects run in the IBC facility.



Work in the clean rooms.

THE FIRST SPIN-OFF COMPANIES HAVE ALREADY MOVED THEIR OFFICES INTO THE IBC

BIOINOVA, s.r.o.



Biolnova, s.r.o. is a subsidiary of the IEM, charged with the transfer of the IEM's intellectual property into practice. It mainly focuses on the operation of the new Innovation Biomedical Center (IBC) facilities and its Business Incubator for spin-off companies planning to develop innovative medical products based on current advances in cell therapy. The IBC is positioned in the high-end market as a specialized Business Incubator equipped with cutting edge clean rooms. Moreover, Biolnova provides all necessary Good Manufacturing Practice (GMP) services for various companies and institutions for the development of modern medical products.

The mission of Biolnova is to stimulate the startup, dynamic development and commercial success of innovative spin-off companies commercializing the scientific outputs of the IEM.

CHONDROS, s.r.o.

Chondros, s.r.o. provides complex solutions in the field of the biomedical treatment of locomotor injuries and cartilage replacement implants.

TATAA MOLECULAR DIAGNOSTICS, s.r.o.

TATAA Molecular Diagnostics, s.r.o. is a TATAA diagnostics facility providing diagnostic detection and analysis of circulating tumor cells in the blood of breast cancer patients.

STUDENT SCIENCE, s.r.o.

Student Science, s.r.o. is a spin-off company that emerged from the scientific output of the IEM in the field of autologous cartilage replacement therapy. The company's know-how includes methods for the cultivation of autologous cartilage cells and the production of innovative cartilage replacement implants.

CB BIO, s.r.o.

CB Bio, s.r.o. performs contract research under GLP requirements on small laboratory animals and is well established among Czech CRO's and small pharmaceutical companies.

MRSUPPORT, s.r.o.

MRsupport, s.r.o. provides magnetic resonance software for specialized image enhancing, suitable, e. g., for visualizing cells labeled with superparamagnetic iron oxide nanoparticles in a living organism.

CELLNOVA, s.r.o.

CellNova, s.r.o. is a spin-off company that emerged from the IEM's scientific output in the field of mesenchymal stem cell therapy. The company's know-how extends to methods for the cultivation of mesenchymal stem cells and their therapeutic application.



The Science and Technology Parks (STP) Association of the CR has accredited IBC to join the CR National Network of STP according to these criteria: sorted out issues of the owner-founder-operator, incubator of small and medium innovation companies, technology transfer, education in innovative entrepreneurship, technical and consulting services of good quality, active part of the innovative infrastructure.